140 related articles for article (PubMed ID: 29030451)
1. Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers.
Roberts RO; Knopman DS; Syrjanen JA; Aakre JA; Vassilaki M; Kremers WK; Mielke MM; Machulda MM; Graff-Radford J; Geda YE; Vemuri P; Lowe V; Jack CR; Petersen RC
Neurology; 2017 Nov; 89(20):2039-2048. PubMed ID: 29030451
[TBL] [Abstract][Full Text] [Related]
2. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.
Jack CR; Wiste HJ; Weigand SD; Therneau TM; Knopman DS; Lowe V; Vemuri P; Mielke MM; Roberts RO; Machulda MM; Senjem ML; Gunter JL; Rocca WA; Petersen RC
Lancet Neurol; 2017 Jun; 16(6):435-444. PubMed ID: 28456479
[TBL] [Abstract][Full Text] [Related]
3. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings.
Jack CR; Wiste HJ; Weigand SD; Knopman DS; Mielke MM; Vemuri P; Lowe V; Senjem ML; Gunter JL; Reyes D; Machulda MM; Roberts R; Petersen RC
Brain; 2015 Dec; 138(Pt 12):3747-59. PubMed ID: 26428666
[TBL] [Abstract][Full Text] [Related]
4. Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals.
Vassilaki M; Christianson TJ; Mielke MM; Geda YE; Kremers WK; Machulda MM; Knopman DS; Petersen RC; Lowe VJ; Jack CR; Roberts RO
Ann Neurol; 2017 Jun; 81(6):871-882. PubMed ID: 28543731
[TBL] [Abstract][Full Text] [Related]
5. Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia.
Vassilaki M; Aakre JA; Kremers WK; Mielke MM; Geda YE; Machulda MM; Knopman DS; Coloma PM; Schauble B; Vemuri P; Lowe VJ; Jack CR; Petersen RC; Roberts RO
J Am Geriatr Soc; 2018 Dec; 66(12):2274-2281. PubMed ID: 30462843
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.
Ossenkoppele R; Jansen WJ; Rabinovici GD; Knol DL; van der Flier WM; van Berckel BN; Scheltens P; Visser PJ; ; Verfaillie SC; Zwan MD; Adriaanse SM; Lammertsma AA; Barkhof F; Jagust WJ; Miller BL; Rosen HJ; Landau SM; Villemagne VL; Rowe CC; Lee DY; Na DL; Seo SW; Sarazin M; Roe CM; Sabri O; Barthel H; Koglin N; Hodges J; Leyton CE; Vandenberghe R; van Laere K; Drzezga A; Forster S; Grimmer T; Sánchez-Juan P; Carril JM; Mok V; Camus V; Klunk WE; Cohen AD; Meyer PT; Hellwig S; Newberg A; Frederiksen KS; Fleisher AS; Mintun MA; Wolk DA; Nordberg A; Rinne JO; Chételat G; Lleo A; Blesa R; Fortea J; Madsen K; Rodrigue KM; Brooks DJ
JAMA; 2015 May; 313(19):1939-49. PubMed ID: 25988463
[TBL] [Abstract][Full Text] [Related]
7. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer's Disease.
Quenon L; Dricot L; Woodard JL; Hanseeuw B; Gilis N; Lhommel R; Ivanoiu A
J Int Neuropsychol Soc; 2016 Nov; 22(10):991-1004. PubMed ID: 27903329
[TBL] [Abstract][Full Text] [Related]
10. Brain amyloid, cortical thickness, and changes in activities of daily living.
Vassilaki M; Aakre JA; Kremers WK; Lesnick TG; Mielke MM; Geda YE; Machulda MM; Knopman DS; Butler L; Traber M; Vemuri P; Lowe VJ; Jack CR; Roberts RO; Petersen RC
Ann Clin Transl Neurol; 2020 Apr; 7(4):474-485. PubMed ID: 32314554
[TBL] [Abstract][Full Text] [Related]
11. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
12. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span.
Jack CR; Wiste HJ; Weigand SD; Knopman DS; Vemuri P; Mielke MM; Lowe V; Senjem ML; Gunter JL; Machulda MM; Gregg BE; Pankratz VS; Rocca WA; Petersen RC
JAMA Neurol; 2015 May; 72(5):511-9. PubMed ID: 25775353
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease.
McDonough IM; Bischof GN; Kennedy KM; Rodrigue KM; Farrell ME; Park DC
Neurobiol Aging; 2016 Oct; 46():68-75. PubMed ID: 27460151
[TBL] [Abstract][Full Text] [Related]
14. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
15. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
[TBL] [Abstract][Full Text] [Related]
16. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
[TBL] [Abstract][Full Text] [Related]
17. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes mellitus and biomarkers of neurodegeneration.
Moran C; Beare R; Phan TG; Bruce DG; Callisaya ML; Srikanth V;
Neurology; 2015 Sep; 85(13):1123-30. PubMed ID: 26333802
[TBL] [Abstract][Full Text] [Related]
19. Amyloid imaging.
Villemagne VL; Rowe CC
Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S41-9. PubMed ID: 21729418
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
